Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Apr;59(4):645–649. doi: 10.1038/bjc.1989.131

Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.

P Lagarde 1, F Bonichon 1, H Eghbali 1, I de Mascarel 1, J Chauvergne 1, B Hoerni 1
PMCID: PMC2247159  PMID: 2713252

Abstract

From 1972 to 1976, 95 patients with clinical stages I-IIIA Hodgkin's disease were treated by chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) before and after extended field radiotherapy. The CVPP schedule gave: (1) a constant drug dosage for each patient independent of body surface or weight; and (2) a total drug dosage dependent on haematological tolerance, since the treatment was given for 21 days or until the leukocyte count dropped to 2 x 10(9) l-1. The drug dosage per unit body surface (or 'dose density') significantly correlates with the drop in leukocyte count (P less than 0.001) and the tumour regression at the end of the induction course (P = 0.020). Disease-free survival is significantly related to dose density (P = 0.050) but not to dose intensity calculated on the duration of treatment (P = 0.240). However, after exclusion of three marginal recurrences due to border-line radiotherapy, the dose intensity significantly correlates with the disease-free survival (P = 0.031) and with the duration of complete remission (r = 0.870).

Full text

PDF
645

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloomfield C. D., Weiss R. B., Fortuny I., Vosika G., Kennedy B. J. Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP. Cancer. 1976 Jul;38(1):42–48. doi: 10.1002/1097-0142(197607)38:1<42::aid-cncr2820380108>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  2. Carde P., MacKintosh F. R., Rosenberg S. A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983 Feb;1(2):146–153. doi: 10.1200/JCO.1983.1.2.146. [DOI] [PubMed] [Google Scholar]
  3. Chauvergne J., Hoerni B., Durand M. Langage commun dans l'expression des résultats thérapeutiques en cancérologie. Bull Cancer. 1974 Apr-Jun;61(2):235–244. [PubMed] [Google Scholar]
  4. Chauvergne J., Hoerni B., Hoerni-Simon G., Durand M., Lagarde C. Chimiothérapie de la maladie de Hodgkin associant procarbazine, vinblastine, cyclophosphamide et méthyl-prednisolone. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1973 Nov 1;80(2):179–188. doi: 10.1007/BF00305134. [DOI] [PubMed] [Google Scholar]
  5. De Vita V. T., Jr, Hubbard S. M., Longo D. L. The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987 Nov 15;47(22):5810–5824. [PubMed] [Google Scholar]
  6. Diggs C. H., Wiernik P. H., Levi J. A., Kvols L. K. Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease. Cancer. 1977 May;39(5):1949–1954. doi: 10.1002/1097-0142(197705)39:5<1949::aid-cncr2820390506>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  7. Eghbali H., Hoerni-Simon G., Durand M., Chauvergne J., Touchard J., Hoerni B. Hodgkin's disease treated by chemotherapy and large field irradiation. Hematologic effects. Acta Radiol Oncol Radiat Phys Biol. 1978;17(4):289–295. doi: 10.3109/02841867809127931. [DOI] [PubMed] [Google Scholar]
  8. Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6. [DOI] [PubMed] [Google Scholar]
  9. Green J. A., Dawson A. A., Fell L. F., Murray S. Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol. 1980 May;9(5):511–514. doi: 10.1111/j.1365-2125.1980.tb05847.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hoerni B., Eghbali H., Durand M., de Mascarel A., Marée D., Hoerni-Simon G., Richaud P., Chauvergne J., Lagarde C. Hodgkin's disease, clinical stages I and II. Results of radical irradiation with or without chemotherapy. Acta Radiol Oncol. 1980;19(3):183–191. doi: 10.3109/02841868009130151. [DOI] [PubMed] [Google Scholar]
  11. Hryniuk W. M. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol. 1987 Mar;14(1):65–74. [PubMed] [Google Scholar]
  12. Hryniuk W. M., Levine M. N., Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr. 1986;(1):87–94. [PubMed] [Google Scholar]
  13. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984 Nov;2(11):1281–1288. doi: 10.1200/JCO.1984.2.11.1281. [DOI] [PubMed] [Google Scholar]
  14. Hryniuk W., Levine M. N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986 Aug;4(8):1162–1170. doi: 10.1200/JCO.1986.4.8.1162. [DOI] [PubMed] [Google Scholar]
  15. Kaplan H. S. Clinical evaluation and radiotherapeutic management of Hodgkin's disease and the malignant lymphomas. N Engl J Med. 1968 Apr 18;278(16):892–899. doi: 10.1056/NEJM196804182781606. [DOI] [PubMed] [Google Scholar]
  16. Lagarde C., Chauvergne J., Durand M., Hoerni B., Hoerni-Simon G., Touchard J. Intérêt d'une chimiothérapie complémentaire de la radiothérapie dans les stades I et II de la maladie de Hodgkin. Bull Cancer. 1975 Jan-Mar;62(1):1–10. [PubMed] [Google Scholar]
  17. Lagarde C., Touchard J., Chauvergne J., Hoerni B. Limites de la radiothérapie dans les formes réticulaires de la maladie de Hodgkin. J Radiol Electrol Med Nucl. 1971 Mar-Apr;52(3):153–155. [PubMed] [Google Scholar]
  18. Lagarde P., Eghbali H., Bonichon F., de Mascarel I., Chauvergne J., Hoerni B. Brief chemotherapy associated with extended field radiotherapy in Hodgkin's disease. Long-term results in a series of 102 patients with clinical stages I-IIIA. Eur J Cancer Clin Oncol. 1988 Jul;24(7):1191–1198. doi: 10.1016/0277-5379(88)90127-7. [DOI] [PubMed] [Google Scholar]
  19. Morgenfeld M., Somoza N., Magnasco J., Pavlovsky S., de Bonesana A. C., Bezares R., Suárez A., Pileggi J., Lein J. M., Macchi A. Combined chemotherapy cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) vs. CVPP plus CCNU (CCVPP) in Hodgin's disease. Cancer. 1979 May;43(5):1579–1586. doi: 10.1002/1097-0142(197905)43:5<1579::aid-cncr2820430502>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES